It was a collaborative effort where my thoughts, comments and observations were welcomed and incorporated into the demand presented to my former employer
Other risk factors include: Pre-existing dry mouth conditions (Sjgrens syndrome, medication-induced xerostomia) High baseline sugar intake combined with reduced saliva Irregular dental care habits before starting GLP-1 therapy Older age , where enamel and gum tissue are already more vulnerable Rapid, substantial weight loss (over 1015% of body weight in a short period) Patients in these categories should be especially vigilant about oral health and consult their dentist proactively
Since many people with Hashimotos struggle with weight gain due to a slower metabolism, GLP-1 medications can be a valuable tool for weight management
Gastrointestinal effects: the main titration bottleneck Nausea, diarrhea, constipation, and vomiting run around 40 to 44% overall, dose-dependent in how many people report them but mild-dominant in severity: severe events stay at or below about 1.7% in any category even at the top dose. In the obesity program the by-dose rates run nausea 25/29/28%, diarrhea 19/21/23%, and vomiting 8/11/13% at 5/10/15 mg. They concentrate during escalation and ease with time on a held dose
The group of them is the Advanced Cataract Protocol
A Waters Symmetry reverse-phase C18 column (2.1 mm 150 mm, 3.5 m) was used for the LC separation as described ( 8 and PGB 2 ] were monitored